Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 8, 2025
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 -
- Expected Cash Runway Extended Through the First Half of 2028 -
Read more at globenewswire.comNASDAQ:ACRS (7/3/2025, 10:52:59 AM)
1.475
+0.03 (+1.72%)
Find more stocks in the Stock Screener
